Home The Word Brain My Amedeo FAQ Privacy About   


C49

In our changing world, speaking just English isn't enough. Open new doors with skills in another world language.

Start with 7 words a day.

Next week: +49.


  HIV Infection

  Free Subscription


07.04.2025

11 AIDS
1 AIDS Res Hum Retroviruses
2 Ann Intern Med
1 Antimicrob Agents Chemother
2 BMJ
7 Clin Infect Dis
4 HIV Med
32 J Acquir Immune Defic Syndr
2 J Clin Invest
2 J Infect Dis
2 J Med Virol
1 Lancet
2 Lancet Infect Dis
1 N Engl J Med
1 Nature
7 PLoS One
4 PLoS Pathog
2 Proc Natl Acad Sci U S A
4 Vaccine


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. MARTINSON T, Heise MJ, Sassaman K, Schmidt HR, et al
    Interest and disparities in awareness and uptake of doxyPEP among U.S. MSM living with HIV.
    AIDS. 2025 Mar 27. doi: 10.1097/QAD.0000000000004192.
    PubMed         Abstract available

  2. LIN LY, Ferte T, Chachage M, Casteano C, et al
    Deciphering HIV vaccine-induced Antibody response according to ethnicity.
    AIDS. 2025 Mar 31. doi: 10.1097/QAD.0000000000004196.
    PubMed         Abstract available

  3. KAMITANI E, DeLuca JB, Mizuno Y
    Systematic review of infodemiology studies using artificial intelligence: social media posts on HIV pre-exposure prophylaxis.
    AIDS. 2025 Mar 27. doi: 10.1097/QAD.0000000000004193.
    PubMed         Abstract available

  4. YANG GW, Zhou QW, Zhen X, Yang Y, et al
    A promising prognostic model for patients with AIDS-related lymphoma in the cART era.
    AIDS. 2025 Apr 1. doi: 10.1097/QAD.0000000000004197.
    PubMed         Abstract available

  5. RIOS-VAZQUEZ V, Vos WAJW, Blaauw MJT, Van Eekeren LE, et al
    Dolutegravir plus lamivudine downregulates cellular stress responses versus three-drug HIV Regimens.
    AIDS. 2025 Apr 1. doi: 10.1097/QAD.0000000000004198.
    PubMed         Abstract available

  6. MOLLAN KR, Pence BW, Westreich D, Bula A, et al
    Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women living with HIV on efavirenz: a prospective cohort study.
    AIDS. 2025 Apr 3. doi: 10.1097/QAD.0000000000004201.
    PubMed         Abstract available

  7. PARCZEWSKI M, Boesecke C, Khaykin P, Jilich D, et al
    Provision of care for people with HIV migrating from Ukraine: preparing for a long-term response.
    AIDS. 2025;39:629-638.
    PubMed         Abstract available

  8. MELDRUM BG, McGee-Avila JK, Luo Q, Milan J Jr, et al
    Racial disparities in cancer risk among MSM with HIV in the United States.
    AIDS. 2025;39:728-736.
    PubMed         Abstract available

  9. HATCHER AM, Metheny N, Dunkle KL, Fielding-Miller R, et al
    A refusal to abandon HIV science.
    AIDS. 2025;39:768-770.
    PubMed        

  10. BUSZA J, Machingura F, Kujeke T, Makamba M, et al
    What happened with preexposure prophylaxis uptake among female sex workers in Zimbabwe? Implications for future prevention programmes.
    AIDS. 2025;39:771-773.
    PubMed        

  11. BENZEKRI NA, Plaisy MK, Koffi JJ, Mensah E, et al
    Food insecurity and mental health outcomes among people living with HIV in West Africa.
    AIDS. 2025 Apr 3. doi: 10.1097/QAD.0000000000004200.
    PubMed         Abstract available


    AIDS Res Hum Retroviruses

  12. NOLAN DJ, Fogel GB, DaRoza J, Rose R, et al
    Indicators for Increased Likelihood of Epidemic Kaposi Sarcoma Progression after Antiretroviral Therapy Initiation.
    AIDS Res Hum Retroviruses. 2025 Apr 3. doi: 10.1089/aid.2025.0007.
    PubMed         Abstract available


    Ann Intern Med

  13. ZAR FA
    In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00552.
    PubMed         Abstract available

  14. HAMED HKA, Nachman A, Riopel N, Schuster M, et al
    Infectious Diseases: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00925.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  15. SAWE S, Tsirizani L, Court R, Gausi K, et al
    The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
    PubMed         Abstract available


    BMJ

  16. BRADSHAW D
    HIV in primary care: further considerations.
    BMJ. 2025;389:r639.
    PubMed        

  17. LOOI MK, Dyer O
    Trump watch: HIV/AIDS research sent into crisis, growing hostility to mRNA vaccines, and more.
    BMJ. 2025;388:r645.
    PubMed        


    Clin Infect Dis

  18. GARCIA-RUIZ DE MORALES AG, Suarez Robles M, Perez-Elias MJ, Negredo E, et al
    Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Clin Infect Dis. 2025 Mar 28:ciae645. doi: 10.1093.
    PubMed         Abstract available

  19. GUARALDI G, Milic J
    A Metabolic Health Framework to Interpret Weight Gain Studies in People With Human Immunodeficiency Virus.
    Clin Infect Dis. 2025 Mar 28:ciae646. doi: 10.1093.
    PubMed        

  20. STEAD D, Wasserman S, Steenkamp E, Parrish A, et al
    Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa.
    Clin Infect Dis. 2025 Apr 2:ciaf080. doi: 10.1093.
    PubMed         Abstract available

  21. WENSING AM, Charpentier C, Calvez V, Ceccherini-Silberstein F, et al
    Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
    Clin Infect Dis. 2025 Apr 3:ciaf161. doi: 10.1093.
    PubMed         Abstract available

  22. ZHU W, Delaney K, Huang YA, Patel RR, et al
    Real-world HIV RNA and antigen/antibody testing among people who use long-acting injectable PrEP.
    Clin Infect Dis. 2025 Apr 3:ciaf173. doi: 10.1093.
    PubMed         Abstract available

  23. RIVERA-VILLEGAS H, Caro-Vega Y, Trujillo-Gamboa A, Lopez-Iniguez A, et al
    Differences in mortality in hospitalized advanced HIV disease between treatment-naive and treatment-discontinuing individuals: a comparative retrospective study from Mexico City.
    Clin Infect Dis. 2025 Apr 3:ciaf175. doi: 10.1093.
    PubMed         Abstract available

  24. DAVY-MENDEZ T, Napravnik S, Hogan BC, Eron JJ, et al
    Changes in the prevalence of non-AIDS conditions among hospitalized persons with HIV in the United States and Canada, 2008-2018.
    Clin Infect Dis. 2025 Apr 2:ciaf167. doi: 10.1093.
    PubMed         Abstract available


    HIV Med

  25. AKSAK-WAS B, Skonieczna-Zydecka K, Parczewski M, Hrynkiewicz R, et al
    Rethinking HIV treatment: How non-integrase strand regimens may hold the key to better immune health.
    HIV Med. 2025 Mar 28. doi: 10.1111/hiv.70020.
    PubMed         Abstract available

  26. BARTOVSKA Z, Massmann R, Jilich D, Groh T, et al
    Late diagnosis of HIV among Ukrainian refugees in the Czech Republic: A retrospective, observational study.
    HIV Med. 2025 Mar 29. doi: 10.1111/hiv.70021.
    PubMed         Abstract available

  27. CHACHU KH, Maboe KA
    Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.
    HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70022.
    PubMed         Abstract available

  28. ZHAO J, Gao M, Zhao D, Tian W, et al
    Prevalence of late HIV diagnosis and its impact on mortality: A comprehensive systematic review and meta-analysis.
    HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70023.
    PubMed         Abstract available


    J Acquir Immune Defic Syndr

  29. NOWOTNY KM, Culbertson K, Akiyama MJ, Callen E, et al
    Integrating People With Lived Experience of Carceral System Involvement Into Research: Lessons Learned From Ending the HIV Epidemic Research Teams.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  30. RODRIGUEZ-DIAZ CE, Jaramillo J, Santiago-Rivera Y, Harkness A, et al
    Language Justice in Implementation Science: Experiences Working With Latinxs to End the HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  31. SHAH HS, Serrano PA, Rodriguez-Diaz CE, Page KR, et al
    Not a Monolith: Regional HIV Implementation Science Lessons With Latino/a/x Populations.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  32. MACAPAGAL K, Stoner MCD, Guss CE, Sukhija-Cohen AC, et al
    Lessons Learned in Engaging Adolescents and Young Adults to End the US HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  33. RODRIGUEZ-DIAZ CE, Kopeka MP, Tun W, Santiago-Rodriguez EI, et al
    Communities Started the End of the HIV Epidemic: Experiences With and Recommendations for Conducting Community-Engaged HIV Implementation Research.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  34. LANZI RG, Varley A, Ott C, Wolfner C, et al
    Implementation Science Methods, Challenges, and Associated Solutions: Transportable Lessons Learned and Best Practices From the Second National Meeting for Research and Community Collaboration Toward Ending the HIV Epidemic in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  35. SCHWARTZ S, Benbow N, Brewer RA, Beres LK, et al
    Generating Evidence for Effective HIV Implementation at Scale: The Value and Feasibility of a Network for Implementation Science in HIV.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  36. SIMON CL, Carlisle NA, Kermani M, Cole C, et al
    Community Engagement to Empowerment: Emphasizing Relationships, Process, Resources, and Context to Strengthen Community Engagement in EHE Research Partnerships.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  37. BERES LK, Harkness A, Corcoran J, Datar R, et al
    Improving Community-Engaged Implementation Science: Perspectives From "Ending the HIV Epidemic" Supplement Award Cases in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  38. DATAR R, Schwartz S, Gomez W, Katz DA, et al
    Community-Engaged Research in HIV Implementation Science: Characterizing Academic and Community Partnerships in the "Ending the HIV Epidemic" Supplement Awards.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  39. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  40. GORDON C, Koenig LJ, Psihopaidas D, Refsland E, et al
    Leveraging Implementation Science to End the HIV Epidemic in the United States: Progress and Opportunities for Federal Agencies.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  41. LI DH, Gaines Lanzi R, Pyra M
    Progress and Priorities to End the HIV Epidemic by 2030: Combined Lessons From 120 US Implementation Research Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  42. GOYAL R, Honerkamp-Smith G, Wells A, Little SJ, et al
    Predictive models to identify individuals with HIV at risk of unsuppressed viral load using routine public health data.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003670.
    PubMed         Abstract available

  43. SHARMA A, Hoover DR, Shi Q, Daubert E, et al
    Poor Sleep Quality is Associated with Frailty Among Women with and without HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003668.
    PubMed         Abstract available

  44. EDWARDS KA, Smith KJ, Jones KF, Bair MJ, et al
    Cost-Effectiveness of a Tailored Pain Self-Management Intervention Compared to Enhanced Usual Care Among People with HIV and Chronic Pain: An Economic Evaluation.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003671.
    PubMed         Abstract available

  45. ELBUR AI, Mirzazadeh A, Tate M, Suprasert B, et al
    HIV Incidence among People Who Inject Drugs, San Francisco, 2022.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003673.
    PubMed         Abstract available

  46. FISHER SA, Jao J, Yee LM, Serghides L, et al
    Fatty acid signatures in people with HIV: association with adverse pregnancy outcomes and offspring anthropometrics.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003665.
    PubMed         Abstract available

  47. DUNK CE, Powis KM, Legbedze J, Sun S, et al
    Low placental growth factor levels mid-gestation predict small for gestational age in pregnant women with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003672.
    PubMed         Abstract available

  48. REMERA E, Chammartin F, Nsanzimana S, Malamba SS, et al
    Factors associated with recent HIV infections among newly HIV diagnosed in Rwanda.
    J Acquir Immune Defic Syndr. 2025 Apr 2. doi: 10.1097/QAI.0000000000003669.
    PubMed         Abstract available

  49. DONOSO VA, Chandra S, Zamantakis A, Kassanits J, et al
    Two Pilots of an Implementation Science Training Program for HIV Prevention and Care Service Providers: Lessons Learned and Future Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  50. KHOSROPOUR CM, Means AR, Kerani RP, Murphy EM, et al
    Developing Implementation Science Capacity Within Health Departments Located in Ending the HIV Epidemic Priority Areas.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  51. OGUNBAJO A, Martinez O, Akiyama M, Dombrowski JC, et al
    Implementation Science Approaches to Addressing the Social and Structural Determinants of Health of Criminal-Legal Involved People Living With HIV to Improve HIV Care Outcomes.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  52. GIGUERE R, Mmeje O, Patel VV, Felsen UR, et al
    Defining Study Populations in HIV Prevention Implementation Science Studies: A Case Comparison of 3 Ending the HIV Epidemic Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  53. BELTRAN RM, Katomski AS, Bonett S, Cianelli R, et al
    Lessons Learned From Engaging Healthcare Providers in Research on Implementation of HIV Preexposure Prophylaxis.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  54. JONES JL, Schwartz S, Kassanits JE, Pyra M, et al
    Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded Clinics: Results From a Multisite Survey.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  55. BROWN LL, Batchelder AW, Gondre-Lewis MC, Willie TC, et al
    Innovations to Address Unmet Behavioral Health Needs in National Ending the HIV Epidemic Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  56. MANTELL JE, Bauman LJ, Bonett S, Buchbinder S, et al
    Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United States: Expanding Access in Nontraditional Settings.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  57. MCCOY K, Mantell JE, Deiss R, Liu A, et al
    Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  58. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 Ending the HIV Epidemic Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  59. KATOMSKI AS, Pachicano AM, Zamantakis A, Benbow ND, et al
    Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite Qualitative Study.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available

  60. GARNER BR, Bouris A, Charlebois ED, Li DH, et al
    The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed         Abstract available


    J Clin Invest

  61. SETIABUDIAWAN TP, Hill PC, DiNardo AR, van Crevel R, et al
    Insights into protection against Mycobacterium tuberculosis infection: time to officially confirm another phenotype?
    J Clin Invest. 2025;135:e191423.
    PubMed         Abstract available

  62. VIOLARI A, Otwombe K, Hahn W, Chen S, et al
    Safety and implementation of phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns.
    J Clin Invest. 2025 Apr 3:e186927. doi: 10.1172/JCI186927.
    PubMed         Abstract available


    J Infect Dis

  63. ERON JJ, Cook PP, Mehrotra ML, Huang H, et al
    Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
    J Infect Dis. 2025 Apr 3:jiaf159. doi: 10.1093.
    PubMed         Abstract available

  64. MUNOZ-MUELA E, Mejias-Trueba M, Serna-Gallego A, Saborido-Alconchel A, et al
    Mitochondrial disorders after 12 months of HIV-1 preexposure prophylaxis based on tenofovir disoproxil fumarate plus emtricitabine in healthy adults.
    J Infect Dis. 2025 Apr 1:jiaf156. doi: 10.1093.
    PubMed         Abstract available


    J Med Virol

  65. TADESE BK, You X, Ndao T, Tota JE, et al
    The Burden of HPV Infections and HPV-Related Diseases Among People With HIV: A Systematic Literature Review.
    J Med Virol. 2025;97:e70274.
    PubMed         Abstract available

  66. BANGWEN E, Berens-Riha N, de Vrij N, Ceulemans A, et al
    No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients.
    J Med Virol. 2025;97:e70320.
    PubMed         Abstract available


    Lancet

  67. AL ZAMEL AM, Saeed AA, Elmubarak M
    Sudan's war and the burden of HIV: a call for urgent intervention.
    Lancet. 2025 Mar 27:S0140-6736(25)00547-1. doi: 10.1016/S0140-6736(25)00547.
    PubMed        


    Lancet Infect Dis

  68. SASO A, Kanteh E, Jeffries D, Okoye M, et al
    The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.
    Lancet Infect Dis. 2025 Mar 25:S1473-3099(25)00072.
    PubMed         Abstract available

  69. LAYTON GR, Veater JB, Thombre R, Afshar B, et al
    Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis.
    Lancet Infect Dis. 2025;25:e253-e254.
    PubMed        


    N Engl J Med

  70. GRAY GE, Venter WDF
    Working at Cross-PURPOSEs to Ending HIV.
    N Engl J Med. 2025;392:1344-1345.
    PubMed        


    Nature

  71. BASILIO H
    Trump team guts AIDS-eradication programme and slashes HIV research grants.
    Nature. 2025 Mar 31. doi: 10.1038/d41586-025-00969.
    PubMed        


    PLoS One

  72. HILL LM, Allison O, Adeniran O, Jones M, et al
    PrEP knowledge and perceptions among women living in North Carolina public housing communities.
    PLoS One. 2025;20:e0320093.
    PubMed         Abstract available

  73. DE BRITO KC, da Silva MFCR, Cardoso CW, Silva LK, et al
    A randomized, controlled trial of a web-based tailored intervention to increase human papillomavirus vaccination among people living with HIV/AIDS.
    PLoS One. 2025;20:e0319646.
    PubMed         Abstract available

  74. ISLEK D, Sanchez T, Baral S, Brown C, et al
    Preferences and willingness for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the US, 2022-2023.
    PLoS One. 2025;20:e0320961.
    PubMed         Abstract available

  75. NAMUWENGE N, Kimuli D, Nsubuga RN, Sserunga T, et al
    Comparison of HIV prevention indicators among adolescent girls and young women in DREAMS and non-DREAMS intervention districts in Uganda.
    PLoS One. 2025;20:e0321277.
    PubMed         Abstract available

  76. KOFFI JJ, Boni SP, Mba L, Bitty-Anderson A, et al
    Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients.
    PLoS One. 2025;20:e0317223.
    PubMed         Abstract available

  77. MUTUKWA M, Kaonga P, Mfula C, Mwansa MM, et al
    Prevalence of detectable viral load and its associated factors among adult patients receiving ART in Choma District, Zambia.
    PLoS One. 2025;20:e0320571.
    PubMed         Abstract available

  78. MOHAMMED YE, Assele DD, Amsalu ST, Tayachew YH, et al
    Prevalence and associated factors of chronic kidney disease among adults receiving antiretroviral therapy at Hawassa University Comprehensive Specialized Hospital.
    PLoS One. 2025;20:e0320787.
    PubMed         Abstract available


    PLoS Pathog

  79. REEVES DB, Litchford M, Fish CS, Farrell-Sherman A, et al
    Intact HIV DNA decays in children with and without complete viral load suppression.
    PLoS Pathog. 2025;21:e1013003.
    PubMed         Abstract available

  80. ZHAO W, Modak A, Ross SR
    DHX15 inhibits mouse APOBEC3 deamination.
    PLoS Pathog. 2025;21:e1013045.
    PubMed         Abstract available

  81. SARKAR S, Kobayashi Y, Russnak T, Shen J, et al
    GS143, an inhibitor of E3 ligase beta-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFkappaB.
    PLoS Pathog. 2025;21:e1013018.
    PubMed         Abstract available

  82. NOORSAEED S, AlBurtamani N, Rokan A, Fassati A, et al
    Heat shock protein 90 is a chaperone regulator of HIV-1 latency.
    PLoS Pathog. 2025;21:e1012524.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  83. NCHIOUA R, Kmiec D, Krchlikova V, Mattes S, et al
    Host ZAP activity correlates with the levels of CpG suppression in primate lentiviruses.
    Proc Natl Acad Sci U S A. 2025;122:e2419489122.
    PubMed         Abstract available

  84. LI C, Burdick RC, Siddiqui R, Janaka SK, et al
    Lenacapavir disrupts HIV-1 core integrity while stabilizing the capsid lattice.
    Proc Natl Acad Sci U S A. 2025;122:e2420497122.
    PubMed         Abstract available


    Vaccine

  85. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed         Abstract available

  86. STRONG C, Joson P, Chu IY, Chuang TT, et al
    Prioritization and barriers of mpox vaccination uptake among gay, bisexual and other men who have sex with men in Taiwan: 2023 HEART survey.
    Vaccine. 2025;53:127059.
    PubMed         Abstract available

  87. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    PubMed         Abstract available

  88. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.